<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01298063</url>
  </required_header>
  <id_info>
    <org_study_id>1200.86</org_study_id>
    <secondary_id>2010-021140-18</secondary_id>
    <nct_id>NCT01298063</nct_id>
  </id_info>
  <brief_title>Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib</brief_title>
  <official_title>Pharmacokinetics, Safety and Tolerability of Different Oral Doses of Afatinib, in Subjects With Mild to Moderate Hepatic Impairment Compared to Healthy Subjects - a Phase I, Single-dose, Open-label, Dose-escalation Study in a Matched Group Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Up to 38 subjects entered with the aim of entering 8 subjects with mild liver impairment (at
      highest dose of afatinib), 8 subjects with moderate liver impairment (at either highest dose
      or two lower doses) and 8 healthy matched controls to each of this two groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve From 0 to Infinity (AUC0-infinity)</measure>
    <time_frame>30 minutes (min) prior to first dosing and 30 min, 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 h, 240 h after first dosing</time_frame>
    <description>AUC0-infinity represents the area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax)</measure>
    <time_frame>30 minutes (min) prior to first dosing and 30 min, 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 h, 240 h after first dosing</time_frame>
    <description>Cmax represents the maximum measured concentration of the analyte in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve From 0 to tz (AUC0-tz)</measure>
    <time_frame>30 minutes (min) prior to first dosing and 30 min, 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 h, 240 h after first dosing</time_frame>
    <description>AUC0-tz represents the area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalitites for Physical Examination, Vital Signs, 12-lead ECG, Clinical Laboratory Tests, Adverse Event, Investigator's Global Tolerability</measure>
    <time_frame>First administration of trial medication until 28 days after last administration of trial medication</time_frame>
    <description>Clinical relevant abnormalitites for physical examination, vital signs, 12-lead electrocardiogramm (ECG), clinical laboratory test (including hematology, clinical chemistry, coagulation, urinalysis), adverse event, investigator's global tolerability. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Liver Diseases</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Afatinib Group A, B (2), D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>healthy subjects, mild and moderate liver impaired subjects to receive one single dose treatment containing the highest dose afatinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Afatinib Group B (3), D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>healthy subjects, moderate liver impaired subjects to receive one single dose treatment containing the medium dose of afatinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Afatinib Group B (1), D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>healthy subjects, moderate liver impaired subjects to receive one single dose treatment containing the low dose of afatinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>1 tablet, once qd in the morning</description>
    <arm_group_label>Afatinib Group A, B (2), D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>1 tablet, once qd in the morning</description>
    <arm_group_label>Afatinib Group B (3), D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>1 tablet, once qd in the morning</description>
    <arm_group_label>Afatinib Group B (1), D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Healthy subjects:

          1. Healthy males and females according to a complete medical history, including a
             physical examination, vital signs (Blood Pressure, Pulse Rate), 12-lead
             Electrocardiogram, and clinical laboratory tests. The healthy subjects must meet the
             matching criteria based on the matching approach (cf. Section 3.3).

          2. Age =18 and =75 years

          3. Body Mass Index =18.5 and =34 kg/m2

          4. Creatinine clearance &gt;70 mL/min according to Cockroft &amp; Gault (for healthy volunteers,
             cf. Section 10.2)

          5. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice and the local legislation. Hepatically impaired
             subjects as determined by a hepatologist/ gastroenterologist:

          6. Male and female liver impaired subjects determined by results of screening classified
             as Child-Pugh A; Child-Pugh score of 5-6 points or as Child-Pugh B; Child-Pugh score
             of 7-9 points, cf. Section 10.2. Child-Pugh criteria must be stable for at least 3
             months prior to screening and during the trial.

          7. Age =18 and =75 years

          8. Body Mass Index =18.5 and =34 kg/m2

          9. Creatinine clearance &gt;40 mL/min according to Cockroft &amp; Gault (for liver impaired
             subjects, cf. Section 10.2)

         10. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice and the local legislation.

             For all females:

         11. Postmenopausal female subjects (postmenopausal defined as at least 1 year of
             spontaneous amenorrhea [in questionable cases or spontaneous amenorrhea below 1 year a
             blood sample with simultaneous follicle stimulating hormone (FSH) above 40 IU/l and
             estradiol below 30 ng/l is confirmatory]) or adequate contraception* for female
             subjects of childbearing potential during the study and until 2 months after study
             completion, e.g. any of the following: implants, injectables, combined oral
             contraceptives, IUD (intrauterine device), sexual abstinence for at least 1 month
             prior to first study drug administration, vasectomised partner (vasectomy performed at
             least 1 year prior to enrolment), or surgical sterilisation (including hysterectomy).
             Females, who do not have a vasectomised partner, are not sexually abstinent or
             surgically sterile have to use an additional barrier method (e.g. condom).

        Exclusion criteria:

        Any relevant deviation from healthy conditions (excluded conditions caused by liver
        impairment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1200.86.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2011</study_first_posted>
  <results_first_submitted>August 8, 2013</results_first_submitted>
  <results_first_submitted_qc>August 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 17, 2013</results_first_posted>
  <last_update_submitted>December 5, 2013</last_update_submitted>
  <last_update_submitted_qc>December 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>50 mg Afatinib Group A</title>
          <description>Group A: Mild hepatic impaired subjects with Child Pugh A were treated with 50 milligram (mg) Afatinib (One tablet qd in the morning).</description>
        </group>
        <group group_id="P2">
          <title>30 mg Afatinib Group B1</title>
          <description>Group B1: Moderate hepatic impaired subjects with Child Pugh B were treated with 30 mg Afatinib (One tablet qd in the morning).</description>
        </group>
        <group group_id="P3">
          <title>50 mg Afatinib Group B2</title>
          <description>Group B2: Moderate hepatic impaired subjects with Child Pugh B were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
        </group>
        <group group_id="P4">
          <title>50 mg Afatinib Group C</title>
          <description>Group C: Subjects with normal hepatic function matching to subjects in group A were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
        </group>
        <group group_id="P5">
          <title>50 mg Afatinib Group D</title>
          <description>Group D: Subjects with normal hepatic function matching to subjects in group B2 were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>50 mg Afatinib Group A</title>
          <description>Group A: Mild hepatic impaired subjects with Child Pugh A were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
        </group>
        <group group_id="B2">
          <title>30 mg Afatinib Group B1</title>
          <description>Group B1: Moderate hepatic impaired subjects with Child Pugh B were treated with 30 mg Afatinib (One tablet qd in the morning).</description>
        </group>
        <group group_id="B3">
          <title>50 mg Afatinib Group B2</title>
          <description>Group B2: Moderate hepatic impaired subjects with Child Pugh B were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
        </group>
        <group group_id="B4">
          <title>50 mg Afatinib Group C</title>
          <description>Group C: Subjects with normal hepatic function matching to subjects in group A were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
        </group>
        <group group_id="B5">
          <title>50 mg Afatinib Group D</title>
          <description>Group D: Subjects with normal hepatic function matching to subjects in group B2 were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="9.0"/>
                    <measurement group_id="B2" value="64.3" spread="6.1"/>
                    <measurement group_id="B3" value="54.8" spread="9.0"/>
                    <measurement group_id="B4" value="55.9" spread="12.6"/>
                    <measurement group_id="B5" value="53.1" spread="7.9"/>
                    <measurement group_id="B6" value="55.3" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under Curve From 0 to Infinity (AUC0-infinity)</title>
        <description>AUC0-infinity represents the area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</description>
        <time_frame>30 minutes (min) prior to first dosing and 30 min, 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 h, 240 h after first dosing</time_frame>
        <population>Pharmacokinetic (PK) analysis set includes all evaluable matched subjects in the treated set providing at least 1 observation for at least 1 PK endpoint without important protocol violations. Group B1 was not included in the primary analysis set for comparison.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Afatinib Group A</title>
            <description>Group A: Mild hepatic impaired subjects with Child Pugh A were treated with 50 milligram (mg) Afatinib (One tablet qd in the morning).</description>
          </group>
          <group group_id="O2">
            <title>30 mg Afatinib Group B1</title>
            <description>Group B1: Moderate hepatic impaired subjects with Child Pugh B were treated with 30 mg Afatinib (One tablet qd in the morning).</description>
          </group>
          <group group_id="O3">
            <title>50 mg Afatinib Group B2</title>
            <description>Group B2: Moderate hepatic impaired subjects with Child Pugh B were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
          </group>
          <group group_id="O4">
            <title>50 mg Afatinib Group C</title>
            <description>Group C: Subjects with normal hepatic function matching to subjects in group A were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
          </group>
          <group group_id="O5">
            <title>50 mg Afatinib Group D</title>
            <description>Group D: Subjects with normal hepatic function matching to subjects in group B2 were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Curve From 0 to Infinity (AUC0-infinity)</title>
          <description>AUC0-infinity represents the area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</description>
          <population>Pharmacokinetic (PK) analysis set includes all evaluable matched subjects in the treated set providing at least 1 observation for at least 1 PK endpoint without important protocol violations. Group B1 was not included in the primary analysis set for comparison.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="886" spread="53.7"/>
                    <measurement group_id="O2" value="552" spread="42.1"/>
                    <measurement group_id="O3" value="934" spread="31.0"/>
                    <measurement group_id="O4" value="956" spread="22.7"/>
                    <measurement group_id="O5" value="985" spread="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative bioavailability</non_inferiority_desc>
            <p_value>0.1998</p_value>
            <p_value_desc>P-value for ratio outside interval 80 - 125 percent</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjusted (by treatment) geometric mean ratio</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>92.64</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>33.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>67.960</ci_lower_limit>
            <ci_upper_limit>126.270</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra individual geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative bioavailability</non_inferiority_desc>
            <p_value>0.1440</p_value>
            <p_value_desc>P-value for ratio outside interval 80 - 125 percent</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjusted (by treatment) geometric mean ratio</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>94.88</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>31.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>72.278</ci_lower_limit>
            <ci_upper_limit>124.549</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra individual geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax)</title>
        <description>Cmax represents the maximum measured concentration of the analyte in plasma</description>
        <time_frame>30 minutes (min) prior to first dosing and 30 min, 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 h, 240 h after first dosing</time_frame>
        <population>PK analysis set. Group B1 was not included in the primary analysis set for comparison.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Afatinib Group A</title>
            <description>Group A: Mild hepatic impaired subjects with Child Pugh A were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
          </group>
          <group group_id="O2">
            <title>30 mg Afatinib Group B1</title>
            <description>Group B1: Moderate hepatic impaired subjects with Child Pugh B were treated with 30 mg Afatinib (One tablet qd in the morning).</description>
          </group>
          <group group_id="O3">
            <title>50 mg Afatinib Group B2</title>
            <description>Group B2: Moderate hepatic impaired subjects with Child Pugh B were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
          </group>
          <group group_id="O4">
            <title>50 mg Afatinib Group C</title>
            <description>Group C: Subjects with normal hepatic function matching to subjects in group A were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
          </group>
          <group group_id="O5">
            <title>50 mg Afatinib Group D</title>
            <description>Group D: Subjects with normal hepatic function matching to subjects in group B2 were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax)</title>
          <description>Cmax represents the maximum measured concentration of the analyte in plasma</description>
          <population>PK analysis set. Group B1 was not included in the primary analysis set for comparison.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="51.7"/>
                    <measurement group_id="O2" value="17.5" spread="44.1"/>
                    <measurement group_id="O3" value="39.5" spread="40.1"/>
                    <measurement group_id="O4" value="30.7" spread="33.7"/>
                    <measurement group_id="O5" value="31.1" spread="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative bioavailability</non_inferiority_desc>
            <p_value>0.2002</p_value>
            <p_value_desc>P-value for ratio outside interval 80 - 125 percent</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjusted (by treatment) geometric mean ratio</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>109.47</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>30.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.683</ci_lower_limit>
            <ci_upper_limit>144.947</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra individual geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative bioavailability</non_inferiority_desc>
            <p_value>0.5281</p_value>
            <p_value_desc>P-value for ratio outside interval 80 - 125 percent</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjusted (by treatment) geometric mean ratio</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>126.89</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>42.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.028</ci_lower_limit>
            <ci_upper_limit>187.159</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra individual geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Curve From 0 to tz (AUC0-tz)</title>
        <description>AUC0-tz represents the area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point</description>
        <time_frame>30 minutes (min) prior to first dosing and 30 min, 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 h, 240 h after first dosing</time_frame>
        <population>PK analysis set. Group B1 was not included in the primary analysis set for comparison.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Afatinib Group A</title>
            <description>Group A: Mild hepatic impaired subjects with Child Pugh A were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
          </group>
          <group group_id="O2">
            <title>30 mg Afatinib Group B1</title>
            <description>Group B1: Moderate hepatic impaired subjects with Child Pugh B were treated with 30 mg Afatinib (One tablet qd in the morning).</description>
          </group>
          <group group_id="O3">
            <title>50 mg Afatinib Group B2</title>
            <description>Group B2: Moderate hepatic impaired subjects with Child Pugh B were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
          </group>
          <group group_id="O4">
            <title>50 mg Afatinib Group C</title>
            <description>Group C: Subjects with normal hepatic function matching to subjects in group A were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
          </group>
          <group group_id="O5">
            <title>50 mg Afatinib Group D</title>
            <description>Group D: Subjects with normal hepatic function matching to subjects in group B2 were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Curve From 0 to tz (AUC0-tz)</title>
          <description>AUC0-tz represents the area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point</description>
          <population>PK analysis set. Group B1 was not included in the primary analysis set for comparison.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="842" spread="50.8"/>
                    <measurement group_id="O2" value="519" spread="39.1"/>
                    <measurement group_id="O3" value="904" spread="31.4"/>
                    <measurement group_id="O4" value="930" spread="22.5"/>
                    <measurement group_id="O5" value="956" spread="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative bioavailability</non_inferiority_desc>
            <p_value>0.2309</p_value>
            <p_value_desc>P-value for ratio outside interval 80 - 125 percent</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjusted (by treatment) geometric mean ratio</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>90.61</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>32.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>66.915</ci_lower_limit>
            <ci_upper_limit>122.705</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra individual geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative bioavailability</non_inferiority_desc>
            <p_value>0.1546</p_value>
            <p_value_desc>P-value for ratio outside interval 80 - 125 percent</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjusted (by treatment) geometric mean ratio</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>94.49</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>32.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>71.563</ci_lower_limit>
            <ci_upper_limit>124.764</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra individual geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalitites for Physical Examination, Vital Signs, 12-lead ECG, Clinical Laboratory Tests, Adverse Event, Investigator's Global Tolerability</title>
        <description>Clinical relevant abnormalitites for physical examination, vital signs, 12-lead electrocardiogramm (ECG), clinical laboratory test (including hematology, clinical chemistry, coagulation, urinalysis), adverse event, investigator's global tolerability. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
        <time_frame>First administration of trial medication until 28 days after last administration of trial medication</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Afatinib Group A</title>
            <description>Group A: Mild hepatic impaired subjects with Child Pugh A were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
          </group>
          <group group_id="O2">
            <title>30 mg Afatinib Group B1</title>
            <description>Group B1: Moderate hepatic impaired subjects with Child Pugh B were treated with 30 mg Afatinib (One tablet qd in the morning).</description>
          </group>
          <group group_id="O3">
            <title>50 mg Afatinib Group B2</title>
            <description>Group B2: Moderate hepatic impaired subjects with Child Pugh B were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
          </group>
          <group group_id="O4">
            <title>50 mg Afatinib Group C</title>
            <description>Group C: Subjects with normal hepatic function matching to subjects in group A were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
          </group>
          <group group_id="O5">
            <title>50 mg Afatinib Group D</title>
            <description>Group D: Subjects with normal hepatic function matching to subjects in group B2 were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalitites for Physical Examination, Vital Signs, 12-lead ECG, Clinical Laboratory Tests, Adverse Event, Investigator's Global Tolerability</title>
          <description>Clinical relevant abnormalitites for physical examination, vital signs, 12-lead electrocardiogramm (ECG), clinical laboratory test (including hematology, clinical chemistry, coagulation, urinalysis), adverse event, investigator's global tolerability. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lipase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperlipasaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First administration of trial medication until 28 days after last administration of trial medication</time_frame>
      <group_list>
        <group group_id="E1">
          <title>50 mg Afatinib Group A</title>
          <description>Group A: Mild hepatic impaired subjects with Child Pugh A were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
        </group>
        <group group_id="E2">
          <title>30 mg Afatinib Group B1</title>
          <description>Group B1: Moderate hepatic impaired subjects with Child Pugh B were treated with 30 mg Afatinib (One tablet qd in the morning).</description>
        </group>
        <group group_id="E3">
          <title>50 mg Afatinib Group B2</title>
          <description>Group B2: Moderate hepatic impaired subjects with Child Pugh B were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
        </group>
        <group group_id="E4">
          <title>50 mg Afatinib Group C</title>
          <description>Group C: Subjects with normal hepatic function matching to subjects in group A were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
        </group>
        <group group_id="E5">
          <title>50 mg Afatinib Group D</title>
          <description>Group D: Subjects with normal hepatic function matching to subjects in group B2 were treated with 50 mg Afatinib (One tablet qd in the morning).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipasaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

